Rigaku Corporation, a Rigaku Holdings Group company and global partner for lab-to-factory X-ray analysis, has developed a patent-pending technology called Electron Density Topography (EDT). The new technology illuminates the structure and dynamic characteristics of biological macromolecules, including antibodies, protein complexes and virus particles, in solution.
EDT enables direct observation of biological macromolecules in solution, reducing artifacts resulting from measurement conditions. EDT is expected to improve R&D processes for innovative biopharmaceutical products, including monoclonal antibody-based therapies and advanced drug delivery systems.
EDT provides information about the general shape, molecular characteristics and internal structure of biological macromolecules from the distribution of electrons that determine the chemical properties of a molecule. EDT has also allowed direct observation of the electron density of biological macromolecules without prior information about the samples.
Also Read: Amphista Therapeutics appoints Antony Mattessich as CEO
In drug discovery, there is a clear need to determine, at the early stages of development, whether a drug has the expected structure and desired characteristics in order to optimize resources. EDT is a technology that meets this requirement and is expected to be used in basic research and in the development of biopharmaceuticals such as antibody drugs.
The first instrument with EDT capabilities will be deployed at Rigaku’s Life Sciences Laboratory, a facility in Cambridge, USA, in the fourth quarter of 2024.
Rigaku is committed to expanding its operations in the life sciences field, strengthening its presence to drive further innovations in collaboration with customers.
SOURCE: Businesswire